Keryx Biopharmaceuticals PT Lowered to $32.00 (KERX)
Analysts at Mizuho lowered their target price on shares of Keryx Biopharmaceuticals (NASDAQ:KERX) from $34.00 to $32.00 in a research report issued to clients and investors on Friday, AnalystRatings.Net reports. Mizuho’s price objective suggests a potential upside of 164.24% from the company’s current price.
Keryx Biopharmaceuticals (NASDAQ:KERX) opened at 12.11 on Friday. Keryx Biopharmaceuticals has a 1-year low of $6.61 and a 1-year high of $17.46. The stock has a 50-day moving average of $14.77 and a 200-day moving average of $14.06. The company’s market cap is $1.101 billion. Keryx Biopharmaceuticals also saw a significant growth in short interest in April. As of April 30th, there was short interest totalling 19,885,216 shares, a growth of 12.4% from the April 15th total of 17,690,828 shares. Currently, 22.7% of the company’s stock are sold short. Based on an average trading volume of 2,067,905 shares, the short-interest ratio is presently 9.6 days.
Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its earnings results on Thursday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.08) by $0.07. The company had revenue of $10.00 million for the quarter, compared to the consensus estimate of $9.91 million. During the same quarter last year, the company posted ($0.03) earnings per share. Keryx Biopharmaceuticals’s revenue was up 42.9% compared to the same quarter last year. On average, analysts predict that Keryx Biopharmaceuticals will post $-0.56 earnings per share for the current fiscal year.
A number of other firms have also recently commented on KERX. Analysts at JMP Securities cut their price target on shares of Keryx Biopharmaceuticals from $25.00 to $19.00 in a research note on Friday. Separately, analysts at Ladenburg Thalmann raised their price target on shares of Keryx Biopharmaceuticals from $24.00 to $30.00 in a research note on Friday, April 4th. They now have a “buy” rating on the stock. Finally, analysts at HC Wainwright reiterated a “buy” rating on shares of Keryx Biopharmaceuticals in a research note on Wednesday, April 2nd. Seven research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $25.29.
Keryx Biopharmaceuticals, Inc (NASDAQ:KERX) is focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.